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Undue Pharmaceutical Influence on Psychiatric Practice
May 18, 2010 | Bipolar Disorder [1], Alcohol Abuse [2]By Lisa Cosgrove, PhD [3] and Harold J.
Bursztajn, MD [4]
Questions have also been raised about the extent of industry influence on the American Psychiatric
Association’s diagnostic and treatment guidelines—namely, its DSM and Clinical Practice Guidelines.
Source:

Within the past few years, increasing concerns have arisen about the
ways in which corporate sponsorship of clinical trials and continuing medical education activities
may bias the information that is published and disseminated about the benefits and risks of
medications. 1,2 Questions have also been raised about the extent of industry influence on the
American Psychiatric Association’s diagnostic and treatment guidelines—namely, its DSM and
Clinical Practice Guidelines.3,4
Clinicians are not the only ones concerned about the effect of financial conflicts of interest on health
care. As controversy over the current revision of DSM has spread to the popular media, patients may
also have questions—regardless of whether they articulate them.
What is at stake is the strength and effectiveness of the therapeutic alliance, since the perception,
let alone the reality, of bias will likely erode trust and lead to a diminished response to the clinician
and to treatment. Although pharmaceutical marketing practices have received much attention in
recent years, there are more insidious, but just as powerful, ways in which clinicians may be
receiving misinformation. It is in patients’ and clinicians’ best interest to maintain a healthy dose of
skepticism when reviewing any data on the efficacy and safety of psychotropic medications, however
prestigious the source. Also, healthy skepticism should not be conflated with an antimedication
approach and certainly not with therapeutic nihilism.
Clearly, there exists the potential for bias and misinformation in an industry-dominated climate.
However, a psychiatrist’s treatment of patients need not be undermined by public controversy over
the actions of corporations or professional organizations.
This article explores some of the ethical dilemmas that can arise in today’s challenging climate. In
addition, psychiatrists’ responses to the growing distrust of patients are discussed.
Randomized clinical controlled trials
Randomized clinical trials are described as the gold standard for evaluating the efficacy and safety of
medications. However, this gold standard is sometimes compromised because of inadequate
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methodological design and outcome measures; use of effect sizes that are not clinically meaningful;
failure to report adverse effects; and violation of equipoise, which lead to the approval of “me-too”
drugs that are not safer, less expensive, or more effective than medications already on the
market.5-8 The brief duration of some clinical trials (often 6 to 8 weeks) does not permit sound
judgments about long-term efficacy and safety. Industry sponsorship tends to be associated with
proindustry conclusions, even when those conclusions are not necessarily warranted.5,6 Thus,
convergent validity, ie, the use of different methods, including challenge/dechallenge case reports, is
vital in considering pharmaceutical safety.
Physicians employed by industry as clinical trial and safety directors have an obligation—per
universal principles of medical ethics as well as the AMA code of ethics—to design, implement, and
report clinical trials in a scientifically responsible manner.9,10 Nonetheless, the actions of some
pharmaceutical companies have raised the question about whether the benefits of antidepressants
and atypical antipsychotics are overemphasized and the risks underreported. One study of clinical
trials of psychiatric medications found that “among the 162 randomized, double-blind,
placebo-controlled studies examined, those that reported conflict of interest were 4.9 times more
likely to report positive results.”11
Antidepressants and atypical antipsychotics
A recently published meta-analysis of the efficacy of antidepressants found that “the magnitude of
benefit of antidepressant medication compared with placebo increases with severity of depression
symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate
symptoms.”12 A research team that previously conducted a meta-analysis drew an even stronger
conclusion: “the relationship between initial severity and antidepressant efficacy is attributable to
decreased responsiveness to placebo among very depressed patients rather than increased
responsiveness to medication [authors’ italics].”13 Moreover, pharmaceutical manufacturers do not
have an incentive to ask whether the drugs they produce may have adverse effects.14
Similarly, the assumed superiority of atypical antipsychotics has been called into question. Several
large multicenter studies in both the United States and the United Kingdom, as well as
meta-analyses, have raised questions about the validity of differentiating between typical and
atypical antipsychotics because no “differences in quality of life or effectiveness measures” between
the 2 classes of drugs were found.15 Indeed, there is growing evidence that atypical antidepressants
and antipsychotics are not advantageous for many patients (although they are properly prescribed
for some), and there is increasing evidence of the persistence of adverse effects (eg, sexual
dysfunction, type 2 diabetes mellitus) even after the medications are discontinued. The fact that
prescription patterns have not changed reflects not only a triumph of marketing but also the
strength of decision-making biases.15,16
CHECKPOINTS
? Clinicians are not the only ones concerned about the effect of financial conflicts of interest on health care—patients may also have questions, regardless of whether they articulate them.
? It is in patients’ and clinicians’ best interest to maintain a healthy dose of skepticism when reviewing any data on the efficacy and safety of
psychotropic medications, however prestigious the source.
? Practitioners who read and later recall guidelines typically remember the general recommendations but forget the detailed exceptions and qualifications—indications and benefits are more likely to be remembered than warnings and
contraindications buried in the adverse events section.

DSM and Clinical Practice Guidelines are not immune to industry influence
DSM is often mischaracterized as the bible of psychiatric disorders because of its enormous influence
on clinical practice. As with previous editions of DSM, the proposed revisions for DSM5 give little
attention to adverse effects. Only 2 of more than 700 pages of text of the main body of DSM-IV-TR
deal with diagnosing adverse effects of psychotropic medications, and there the focus is on
movement disorders. Neuroleptic malignant syndrome is given short shrift (1 paragraph). A
discussion of life-threatening adverse effects such as diabetes and other metabolic conditions is
entirely absent. A review of the recently proposed changes to DSM (www.dsm5.org) indicates that
these omissions will remain in the next edition. Approximately 68% of the DSM5 task force report
having ties to the pharmaceutical industry.17 This represents an increase of 20% over the proportion
of DSM-IV task force members with such ties.17,18
Clinical Practice Guidelines, which are used by primary care physicians as well as mental health
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clinicians, exert enormous influence on psychiatric treatment. It is thus imperative that the
recommendations be balanced and accurate, and that they give adequate consideration to informed
consent, alternatives to medications, and information about when to discontinue medications.
However, all of the authors of the Clinical Practice Guidelines for bipolar disorder, for example, had
financial relationships with companies whose drugs were identified as “first-line pharmacological
treatment.”3 Not surprisingly, there is little discussion of how to inform patients of the risks and
benefits of medications, when to discontinue medications, or how to monitor patients for withdrawal
symptoms in the Clinical Practice Guidelines.

Deeper implications for psychiatric practice
People being treated for serious mental illness are often highly vulnerable to distrust. The fear of
psychosis and the hopelessness and helplessness of severe depression can diminish a patient’s
ability to weigh treatment risks, benefits, and alternatives. Such challenges do not mean that
patients cannot navigate complex decision-making processes and that psychiatrists must resort to a
paternalistic model of care.19,20 Patients who believe that their prescribing clinician has their best
interests at heart are better able to engage in shared decision making. A therapeutic alliance
grounded in trust is essential in bringing strength and hope to the lives of individuals with psychiatric
disabilities. When a patient has been informed about the potential adverse effects of a medication,
there is a better chance that he or she will trust the clinician, will adhere to the medication regimen,
and will be receptive to other treatment trials than will a patient for whom a bad outcome is a
devastating surprise.
Beyond the biases that influence the formulation of treatment guidelines, practitioners who read and
later recall those guidelines typically remember the general recommendations but forget the
detailed exceptions and qualifications.21 Warnings and contraindications buried in the adverse
events section of the labeling of a pharmaceutical product are not likely to be as well-remembered
as the indications and benefits that are prominently noted. The consequences of automated thinking
and the irrational persistence in belief may be reinforced by delays in disclosing adverse effects of
medications.21,22 Once clinicians have internalized the mindset that a particular drug is the treatment
of choice for a particular condition, the automatic prescribing habit sets in and becomes difficult to
dislodge. As a result, a pharmaceutical company that engages in such tactics of habituation gains an
unfair competitive advantage over a competitor that makes full and timely disclosures of adverse
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findings.
Recommendations
Although practicing evidence-based medicine can be a useful corrective to uncritical prescribing, it is
no panacea. Unavoidably, we practice under conditions of uncertainty, where every patient exists in
a unique life context, every patient-clinician relationship is in some ways unique, and the next
clinical outcome cannot be known until it occurs.23 Yet this very complexity, to which potential or
real financial conflicts of interests contribute, presents an opportunity to enhance and strengthen the
therapeutic alliance through a mix of clinical wisdom and humility.

The suggestions given in the Table were developed by
soliciting feedback from individuals who represented a range of disciplines and perspectives. For
example, some were social scientists who have publicly questioned the ethics of industry-funded
research, while others were clinicians and academicians who received honoraria for talks sponsored
by pharmaceutical companies, or who received funding for their research. Incorporating feedback
from a wide variety of individuals—both critics of financial conflicts of interest and those with
industry ties—may serve as a model for how professional orga-nizations such as the American
Psychiatric Association can better manage collaborations between industry and academic institutions
and medical schools. Specifically, the goal should be to achieve a meaningful system of checks and
balances. Thus, rather than a ban on individuals with industry ties serving on panels of diagnostic
and treatment guidelines, perhaps a more helpful solution would be to invite critics of industry to
serve alongside individuals who have connections to pharmaceutical companies.
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